JAMA:GLP-1受体激动剂体重控制谁更强?索马鲁肽减重效果优于利拉鲁肽

2022-01-12 MedSci原创 MedSci原创

对于肥胖或超重的非糖尿病患者,每周1次索马鲁肽的减重效果优于每日1次利拉鲁肽

STEP研究证实,每周2.4mg的GLP-1受体激动剂索马鲁肽可有效降低肥胖人群体重,不论其是否患有糖尿病。索马鲁肽是第二个获批用于体重控制的GLP-1受体激动剂,第一个获批药物是利拉鲁肽。近日研究人员考察了在超重或肥胖人群中,每周皮下注射1次2.4 mg索马鲁肽或每日皮下注射1次3.0mg利拉鲁肽的疗效和不良事件差异。


本次研究在美国19个临床中心开展,随访到2021年5月,为随机、公开、为期68周的3b期试验,体重指数在30以上或27并伴有有1个或更多的体重相关合并症,但无糖尿病的患者参与研究,患者在饮食及运动基础上,随机接受每周1次2.4 mg的索马鲁肽(n=126)、每日1次3.0mg的利拉鲁肽(n=127)或安慰剂(n=85)。研究的主要终点为68周体重变化。
患者平均年龄49岁,265名女性,平均体重104.5kg,平均体重指数37.5,319人(94.4%)完成了试验,271人(80.2%)完成了治疗。与基线检查时相比,索马鲁肽组的平均体重变化为-15.8%,利拉鲁肽组为-6.4%,安慰剂组的体重变化为-1.9%。与利拉鲁肽相比,服用索马鲁肽组参与者在体重减轻10%或以上、15%或以上、20%或以上均更有优势,分别为70.9% vs 25.6%(OR=6.3)、55.6%vs12.0%(OR=7.9)、38.5%vs 6.0%(OR=8.2)。索马鲁肽组因任何原因停止治疗率为13.5%,利拉鲁肽组为27.6%。索马鲁肽组胃肠道不良事件报告率为84.1%,利拉鲁肽组为82.7%。

索马鲁肽 vs 利拉鲁肽对体重的控制效果

研究认为,对于肥胖或超重的非糖尿病患者,每周1次索马鲁肽的减重效果优于每日1次利拉鲁肽。
原始出处:
Domenica M. Rubino et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial. JAMA,January 11, 2022。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-02-13 谭正中

    999999?99999

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-17 储酒仙

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-14 yibei
  7. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-13 大美女大美女大美女

    利拉鲁肽牛!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-13 148bdd8em77暂无昵称

    减肥患者

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1214244, encodeId=cb9b1214244a8, content=<a href='/topic/show?id=1090e69928f' target=_blank style='color:#2F92EE;'>#索马鲁肽#</a>比<a href='/topic/show?id=401e3230391' target=_blank style='color:#2F92EE;'>#利拉鲁肽#</a>更厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76992, encryptionId=1090e69928f, topicName=索马鲁肽), TopicDto(id=32303, encryptionId=401e3230391, topicName=利拉鲁肽)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:17:31 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193007, encodeId=087e119300e07, content=999999?99999, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c32c5482594, createdName=谭正中, createdTime=Sun Feb 13 17:05:01 CST 2022, time=2022-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973632, encodeId=348819e363244, content=<a href='/topic/show?id=905526695ad' target=_blank style='color:#2F92EE;'>#体重控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26695, encryptionId=905526695ad, topicName=体重控制)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Sat Apr 09 19:24:57 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185178, encodeId=826511851e860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2462821, createdName=储酒仙, createdTime=Mon Jan 17 13:45:37 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8081, encryptionId=bb0e8081b2, topicName=GLP-1受体激动剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e183245, createdName=Eleven11, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422769, encodeId=14211422e69ea, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627873, encodeId=d61d162e873d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Fri Jan 14 10:24:57 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183890, encodeId=29831183890d4, content=利拉鲁肽牛!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220112/8e26adde329d46e88c2fe2947f5a9c52/5fed729a9b7644b3b9075618d6dd5622.jpg, createdBy=69002313391, createdName=大美女大美女大美女, createdTime=Thu Jan 13 14:55:45 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183793, encodeId=73d31183e93d4, content=减肥患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9b965326650, createdName=148bdd8em77暂无昵称, createdTime=Thu Jan 13 09:11:58 CST 2022, time=2022-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183696, encodeId=f50d1183696fe, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Wed Jan 12 22:47:26 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-12 仁术2021

    不错,学习了。

    0

相关资讯

J RENAL NUTR:利拉鲁肽对脂肪肾的影响——良好的血糖控制可以降低脂肪肾的发生!

肾脏(脂肪肾)异位脂质积聚是糖尿病肾病的潜在驱动因素,严格的血糖控制可以降低糖尿病肾病的风险。

NEJM:中等强度运动+利拉鲁肽(3.0 mg/d)——手把手教你如何健康减肥!

结合运动和利拉鲁肽治疗的策略更能改善健康的减肥维持。

Diabetes Obes Metab:利拉鲁肽与口服降糖药作为附加疗法在单独使用二甲双胍的2型糖尿病患者中维持血糖控制

由于大多数2型糖尿病(T2D)患者是在初级保健中接受治疗的,初级保健临床医生在优化糖尿病管理方面发挥着关键作用。血糖控制的改善和保持与更强的降糖治疗依从性有关,长期保持良好的血糖控制可降低T2D并发症

Antioxidants:GLP-1类似物利拉鲁肽通过减少氧化应激和炎症改善脓毒血症影响的血管功能

利拉鲁肽是一种长效胰高血糖素样肽-1 (GLP-1)的类似物,在食物摄取后释放,参与葡萄糖的调节。

Diabetes Obes Metab:利拉鲁肽治疗1型糖尿病的疗效和安全性

尽管引入了新的胰岛素类似物和血糖监测系统,但对于大多数1型糖尿病患者来说,实现和保持严格的血糖控制仍是困难的。

Diabetes Obes Metab:利拉鲁肽可减少2型糖尿病患者心脏脂肪量

利拉鲁肽治疗26周后可减少心脏脂肪组织。心脏脂肪组织减少与体重减轻无关,表明这不是药物特异性作用。